Evolocumab Beats Zetia for LDL Cholesterol

December 18, 2013 6:52 PM

14 0

Evolocumab Beats Zetia for LDL Cholesterol

The first phase III results for Amgen's investigational anti-PCSK9 human monoclonal antibody -- evolocumab -- indicate the drug outperformed placebo and ezetimibe (Zetia) , the company announced Tuesday.

When used as a stand-alone treatment for patients with elevated cholesterol who were not taking other lipid-lowering therapies, the antibody performed better for percent reduction in LDL cholesterol from baseline to week 12 and the mean percent reduction in LDL cholesterol from baseline at weeks 10 ...

Read more

To category page

Loading...